Trial Outcomes & Findings for Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients (NCT NCT04216784)

NCT ID: NCT04216784

Last Updated: 2025-09-16

Results Overview

Change in weight defined as weight loss of 1 kilogram

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

21 participants

Primary outcome timeframe

2-7 days

Results posted on

2025-09-16

Participant Flow

Participant milestones

Participant milestones
Measure
Furosemide (Lasix) Alone
Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours Furosemide Injection: Patient will receive furosemide intravenously
Combination of Furosemide (Lasix) and Albumin
Cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams IV BID for at least 48 hours Furosemide Injection: Patient will receive furosemide intravenously Albumin Human: Patient will receive albumin (25%) 12.5 gm intravenously
Overall Study
STARTED
10
11
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
10
11

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 2-7 days

Population: Data was not collected for this study. Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. Ultimately this dispute resulted in study termination. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study.

Change in weight defined as weight loss of 1 kilogram

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 2-7 days

Population: Data were not reported or collected. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study.

The amount of urine produced over 24 hours.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Through completion of study, up to an average of 1 year

Population: Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study.

Changes in renal function were observed in patients from the two study arms . Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Through completion of study, up to an average of 1 year

Population: Data was not collected for this study. Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. Ultimately this dispute resulted in study termination. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study

duration of hospital admission Data was not collected for this study. Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. Ultimately this dispute resulted in study termination. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30 days from discharge

Population: Data was not collected for this study. Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. Ultimately this dispute resulted in study termination. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study

Number of occurrences that the patient is readmitted after discharge within 30 days Data was not collected for this study. Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. Ultimately this dispute resulted in study termination. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 1 year

Population: Data was not collected for this study. Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. Ultimately this dispute resulted in study termination. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study

Patient survival rates to be closely monitored in patients from the two study arms Data was not collected for this study. Study was terminated early due to IRB halting study inclusion and data collection due to drug cost (albumin) funding. Ultimately this dispute resulted in study termination. At no point before the study was halted was data collected on patients enrolled into the study, nor is data going to be collected in patients that were enrolled into the study.

Outcome measures

Outcome data not reported

Adverse Events

Furosemide (Lasix) Alone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Combination of Furosemide (Lasix) and Albumin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Lance Lineberger

Rush University Medical Center

Phone: 312-942-5126

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place